Effects of a new flavonoid and myo-inositol supplement on some biomarkers of cardiovascular risk in postmenopausal women: A randomized trial

International Journal of Endocrinology

Volumn 2014, Issue , 2014, Pages

  D'Anna, Rosario ^a   Santamaria, Angelo ^a   Cannata, Maria Letizia ^a   Interdonato, Maria Lieta ^a   Giorgianni, Grazia Maria ^b   Granese, Roberta ^a   Corrado, Francesco ^a   Bitto, Alessandra ^b  

^a UNIVERSITY OF MESSINA   (Italy)

^b UNIVERSITY OF MESSINA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; ALKALINE PHOSPHATASE BONE ISOENZYME; BIOLOGICAL MARKER; FLAVONOID; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INOSITOL; ISOFLAVONE DERIVATIVE; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; PLACEBO; POLYPHENOL; RESISTIN; TRIACYLGLYCEROL;

ADULT; ARTICLE; BLOOD LEVEL; BONE METABOLISM; CACAO; CARDIOVASCULAR RISK; CONTROLLED STUDY; DIET SUPPLEMENTATION; DRUG EFFECT; DRUG RESPONSE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; METABOLIC SYNDROME X; MIDDLE AGED; NATURAL REPLACEMENT THERAPY; OUTCOME ASSESSMENT; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; RISK FACTOR; SOYBEAN; SUBSTITUTION THERAPY;

EID: 84934939558     PISSN: 16878337     EISSN: 16878345     Source Type: Journal    
DOI: 10.1155/2014/653561     Document Type: Article

References (30)

1. World Health Organization, The Global Burden of Disease: 2004 Update,WorldHealth Organization, Geneva, Switzerland, 2008.
2. B. Isomaa, P. Almgren, T. Tuomi et al., "Cardiovascular morbidity and mortality associated with the metabolic syndrome," Diabetes Care, vol. 24, no. 4, pp. 683-689, 2001.
3. T. E. O'Toole, D. J. Conklin, and A. Bhatnagar, "Environmental risk factors for heart disease," Reviews on Environmental Health, vol. 23, no. 3, pp. 167-202, 2008.
4. L. Dauchet, P. Amouyel, and J. Dallongeville, "Fruit and vegetable consumption and risk of stroke: A meta-analysis of cohort studies," Neurology, vol. 65, no. 8, pp. 1193-1197, 2005.
5. L. Jia, X. Liu, Y. Y. Bai et al., "Short-termeffect of cocoa product consumption on lipid profile: A meta-analysis of randomized controlled trials," The American Journal of Clinical Nutrition, vol. 92, no. 1, pp. 218-225, 2010.
6. S. Desch, J. Schmidt, D. Kobler et al., "Effect of cocoa products on blood pressure: Systematic review and meta-analysis," The American Journal of Hypertension, vol. 23, no. 1, pp. 97-103, 2010.
7. P. K. Whelton, J. He, L. J. Appel et al., "Primary prevention of hypertension: Clinical and public health advisory from the National High Blood Pressure Education Program," Journal of the American Medical Association, vol. 288, no. 15, pp. 1882-1888, 2002.
8. F. Hermann, L. E. Spieker, F. Ruschitzka et al., "Dark chocolate improves endothelial and platelet function," Heart, vol. 92, no. 1, pp. 119-120, 2006.
9. M. Atteritano, H. Marini, L. Minutoli et al., "Effects of the phytoestrogen genistein on some predictors of cardiovascular risk in osteopenic, postmenopausal women: A two-year randomized, double-blind, placebo-controlled study," Journal of Clinical Endocrinology and Metabolism, vol. 92, no. 8, pp. 3068-3075, 2007.
10. D. Giordano, F. Corrado, A. Santamaria et al., "Effects ofmyoinositol supplementation in postmenopausal women with metabolic syndrome: A perspective, randomized, placebocontrolled study," Menopause, vol. 18, no. 1, pp. 102-104, 2011.
11. A. Santamaria, D. Giordano, F. Corrado et al., "One-year effects of myo-inositol supplementation in postmenopausal women with metabolic syndrome," Climacteric, vol. 15, no. 5, pp. 490-495, 2012.
12. A. R. Saltiel, "Second messengers of insulin action," Diabetes Care, vol. 13, no. 3, pp. 244-256, 1990.
13. H. Marini, L. Minutoli, F. Polito et al., "Effects of the phytoestrogen genistein on bone metabolism in osteopenic postmenopausal women: A randomized trial," Annals of Internal Medicine, vol. 146, no. 12, pp. 839-847, 2007.
14. F. Squadrito, H. Marini, A. Bitto et al., "Genistein in the metabolic syndrome: Results of a randomized clinical trial," Journal of Clinical Endocrinology andMetabolism, vol. 98, no. 8, pp. 3366-3374, 2013.
15. S. M. Grundy, J. I. Cleeman, S. R. Daniels et al., "Diagnosis and management of the metabolic syndrome: An American heart association/national heart, lung, and blood institute scientific statement," Circulation, vol. 112, no. 17, pp. 2735-2752, 2005.
16. B. Sarriá, S.Martínez-López, J. L. Sierra-Cinos,L.Garciá-Diz, R. Mateos, and L. Bravo, "Regular consumption of a cocoa product improves the cardiometabolic profile in healthy andmoderately hypercholesterolaemic adults," The British Journal of Nutrition, vol. 111, no. 1, pp. 122-134, 2014.
17. L. D. P. Nogueira,M. P. Knibel, M. R. S. G. Torres, J. F. Nogueira Neto, and A. F. Sanjuliani, "Consumption of high-polyphenol dark chocolate improves endothelial function in individuals with stage 1 hypertension and excess bodyweight," International Journal of Hypertension, vol. 2012, Article ID 147321, 9 pages, 2012.
18. T. Yamauchi, J. Kamon, H. Waki et al., "The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity," Nature Medicine, vol. 7, no. 8, pp. 941-946, 2001.
19. P. M. Catalano, M. Hoegh, J. Minium et al., "Adiponectin in human pregnancy: Implications for regulation of glucose and lipid metabolism," Diabetologia, vol. 49, no. 7, pp. 1677-1685, 2006.
20. P.Henneman, A. C. J.W. Janssens, M. C. Zillikens et al., "Menopause impacts the relation of plasma adiponectin levels with the metabolic syndrome," Journal of Internal Medicine, vol. 267, no. 4, pp. 402-409, 2010.
21. D. Grassi, C. Lippi, S. Necozione, G. Desideri, and C. Ferri, "Short-term administration of dark chocolate is followed by a significant increase in insulin sensitivity and a decrease in blood pressure in healthy persons," The American Journal of Clinical Nutrition, vol. 81, no. 3, pp. 611-614, 2005.
22. M. Karim, K. McCormick, and C. Tissa Kappagoda, "Effects of cocoa extracts on endothelium-dependent relaxation," Journal ofNutrition, vol. 130, no. 8S, supplement, pp. 2105S-2108S, 2000.
23. C. L.McTernan, P. G.McTernan, A. L. Harte, P. L. Levick, A. H. Barnett, and S. Kumar, "Resistin, central obesity, and type 2 diabetes," The Lancet, vol. 359, no. 9300, pp. 46-47, 2002.
24. C.M. Steppan, S. T. Bailey, S. Bhat et al., "The hormone resistin links obesity to diabetes," Nature, vol. 409, no. 6818, pp. 307-312, 2001.
25. E. Malo, O. Ukkola, M. Jokela et al., "Resistin is an indicator of the metabolic syndrome according to five different definitions in the Finnish health 2000 survey," Metabolic Syndrome and Related Disorders, vol. 9, no. 3, pp. 203-210, 2011.
26. Y. Chang, D. Chang, K. Lin, S. Shin, and Y. Lee, "Visfatin in overweight/obesity, type 2 diabetes mellitus, insulin resistance, metabolic syndrome and cardiovascular diseases: A metaanalysis and systemic review," Diabetes/Metabolism Research and Reviews, vol. 27, no. 6, pp. 515-527, 2011.
27. J. Kim, S. Kim, J. Im, and D. Lee, "The relationship between visfatin and metabolic syndrome in postmenopausal women," Maturitas, vol. 67, no. 1, pp. 67-71, 2010.
28. P. D. Ross andW. Knowlton, "Rapid bone loss is associated with increased levels of biochemical markers," Journal of Bone and Mineral Research, vol. 13, no. 2, pp. 297-302, 1998.
29. H.Marini, A. Bitto, D. Altavilla et al., "Breast safety and efficacy of genistein aglycone for postmenopausal bone loss: A follow-up study," Journal ofClinical Endocrinology andMetabolism, vol. 93, no. 12, pp. 4787-4796, 2008.
30. Z.Dai, S. K. Chung,D.Miao, K. S. Lau, A. W. H. Chan, and A. W. C. Kung, "Sodium/myo-inositol cotransporter 1 and myoinositol are essential for osteogenesis and bone formation," Journal of Bone and Mineral Research, vol. 26, no. 3, pp. 582-590, 2011.